Novartis (NVS) Stock: Q125 Earnings Beat Boosts Confidence in Oncology and Cardio Drugs

https://coincentral.com/novartis-nvs-stock-q125-earnings-beat-boosts-confidence/
TLDR Novartis reported Q1 2025 EPS of $2.28, beating expectations by 7.55%. Revenue reached $13.23 billion, surpassing estimates and up 11.9% year over year. Strong performance came from Kisqali (+52.5%) and Entresto (+20.3%). Immunology drug Ilaris rose 31.3%, while Cosentyx slightly missed total estimates. The stock is up 21% YTD…